Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Operating Leases (2021 - 2025)

Pliant Therapeutics (PLRX) has disclosed Operating Leases for 5 consecutive years, with $27.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 6.05% to $27.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.7 million, a 6.05% decrease, with the full-year FY2025 number at $27.7 million, down 6.05% from a year prior.
  • Operating Leases was $27.7 million for Q4 2025 at Pliant Therapeutics, down from $29.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $30.0 million in Q2 2025 to a low of $2.3 million in Q2 2023.
  • A 5-year average of $15.6 million and a median of $6.4 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: crashed 64.06% in 2023, then soared 731.58% in 2024.
  • Pliant Therapeutics' Operating Leases stood at $5.3 million in 2021, then crashed by 35.61% to $3.4 million in 2022, then crashed by 32.4% to $2.3 million in 2023, then soared by 1170.02% to $29.4 million in 2024, then dropped by 6.05% to $27.7 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Operating Leases are $27.7 million (Q4 2025), $29.4 million (Q3 2025), and $30.0 million (Q2 2025).